Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Oncology Today with Dr Neil Love
00:00
Efficacy of Oral SERD Monotherapy
Rinath reviews EMERALD results: elacestrant shows PFS benefit particularly in ESR1-mutant and endocrine-sensitive subgroups.
Play episode from 13:48
Transcript
